Item 7.01 Regulation FD Disclosure.
On September 14, 2022, BioCardia, Inc. (the “Company”) issued a press release
announcing that data from its CardiAMP© Cell Therapy Heart Failure pivotal trial
(ClinicalTrials.gov Identifier: NCT02438306), will be presented at the Heart
Failure Society of America Annual Meeting 2022 on October 1, 2022 in a poster
format at 6:10pm entitled, “Autologous Cell Therapy For HFrEF: Efficacy Outcomes
At Two Years For The Roll-in Cohort Of A Phase III Pivotal Trial.” A copy of the
press release is attached hereto as Exhibit 99.1 to this current report on Form
The information furnished pursuant to this Item 7.01, including Exhibit 99.1
hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities under that section, nor shall it be deemed to be incorporated by
reference in any filing made by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, except as otherwise expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated September 14, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses